Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05466370
Other study ID # PRETRACO
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 15, 2022
Est. completion date July 31, 2022

Study information

Verified date April 2023
Source Kepler University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Currently, about 350000 red blood cell concentrates are produced from blood donations in Austria every year. In addition to the main effect of replacing lost blood, red blood cell concentrates also have many undesirable effects - from blood group compatibilities, which are easily avoidable due to care, to storage-related side effects, to mostly intensive care problems as a result of massive transfusions, to system-wide effects such as TRALI, TACO and TRIM. Before being administered to patients, red blood cell concentrates undergo an extensive quality assurance process in which a large number of parameters are collected. Prior to use on patients, for example, bedside tests and tests for further incompatibilities with a blood sample from the intended patient are performed. With the implementation of Patient Blood Management (PBM) in recent years, the use of red cell concentrates has become more targeted - the number of transfusions is decreasing in most developed countries. However, it is still possible to suffer transfusion-related adverse events (TRAE). Thus, active research activity to reduce these TRAEs continues to be called for. To date, however, it is not known which patients experience transfusion-related adverse events. Despite the broad measures of hemovigilance and pre-transfusion testing, it is still not possible to predict which individual patient will respond to a transfusion with a typical adverse event such as hypotension, hemolysis, renal failure, or TRALI. It seems understandable that characteristics of the patient as well as characteristics of the administered unit could play a role for this. In particular, it is conceivable that a combination of characteristics of the blood unit and characteristics of the patient could determine a complication in the course of administration. For this reason, it seems attractive to use artificial intelligence and machine learning methods to predict any complications.


Recruitment information / eligibility

Status Completed
Enrollment 3366
Est. completion date July 31, 2022
Est. primary completion date July 31, 2022
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All adult patients that received at a blood transfusion the Kepler University Hospital in the period between 2016-10-31 to 2020-08-31. Exclusion Criteria: None.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Transfusion of Allogeneic Blood
Transfusion of Allogeneic Blood

Locations

Country Name City State
Austria Kepler University Hospital Linz Upper Austria

Sponsors (1)

Lead Sponsor Collaborator
Kepler University Hospital

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUROC for Classification of AKI AUROC for Classification of AKI 2016-10-31 to 2020-08-31
Primary AUROC for Classification of ARF AUROC for Classification of ARF 2016-10-31 to 2020-08-31
Primary AUROC for Classification of AKI and ARF AUROC for Classification of AKI and ARF 2016-10-31 to 2020-08-31
Secondary Confusion Matrix Confusion Matrix Results: true positives, true negatives, false positive, false negatives and values calculated from these results. 2016-10-31 to 2020-08-31
Secondary Descriptive Statistics Descriptive Statistics (age in years, gender as male/female, blood group as A, B, 0, AB, hemoglobin in g/dl, platelets in count/microliter, leukocytes in cells per liter, CRP in mg/dl, creatinine in mg/dl, GFR ml/minute, glucose in mg/dl, potassium in mmol/l, TT, aPTT in seconds, ALT U/liter, paO2 mmHg, Rhesus type as positive or negative, height in cm, weight in kg, body temperature in kg, age of blood in days, cholesterine in mg/dl, systolic blood pressure in mmHg, diastolic blood pressure in mmHg)
This outcome measure will compare the individual feature (e. g. height in cm) in one group vs. the other. Significant difference will be described by p-value.
2016-10-31 to 2020-08-31
See also
  Status Clinical Trial Phase
Completed NCT02435212 - Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload Phase 2
Recruiting NCT05924100 - Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD Phase 2
Completed NCT04303910 - An Analysis of Blood Management in Patients Having Hip or Knee Arthroplasty
Terminated NCT03643042 - Impact of 2 Transfusion Strategies on Quality of Life of Multitransfused Patients With Low-risk Myelodysplastic Syndrome N/A
Completed NCT04856618 - Machine Learning-Based Prediction of Major Perioperative Allogeneic Blood Requirements in Cardiac Surgery
Not yet recruiting NCT06414031 - Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery Phase 3
Recruiting NCT05462548 - The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study Phase 4
Completed NCT04155021 - Knowledge and Attitude in Perioperative Erythrocyte Transfusion in Medical Personnel in Siriraj Hospital
Active, not recruiting NCT05739097 - Prospective Study on Feto-maternal outcoMe In aNemIc womEn
Completed NCT05203016 - Complications Associated With Intraoperative Hypothermia.
Recruiting NCT03369210 - Liberal Transfusion Strategy in Elderly Patients Phase 3